| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-1369 (D. Del.) | Oct. 2, 2017 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,750,703
9,763,933
9,770,416
9,775,809
|
| Boehringer Ingelheim Pharms., Inc. v. Aurobindo Pharma USA Inc., 17-7887 (D.N.J.) | Oct. 4, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Forest Labs. Holdings, Ltd. v. Strides Pharma Global PTE Ltd., 17-1394 (D. Del.) | Oct. 5, 2017 | Hon. Gregory M. Sleet | Savella® (milnacipran HCl tablets) |
6,602,911
7,888,342
7,994,220
|
| Boehringer Ingelheim Pharms., Inc. v. Hetero USA Inc., 17-7923 (D.N.J.) | Oct. 5, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 17-cv-11923 (D. Mass.) | Oct. 6, 2017 | Hon. F. Dennis Saylor, IV | Xtampza® ER (oxycodone extended-release capsules)XXOxyContin® (oxycodone HCl extended-release tablets) |
9,522,919
9,073,933
|
| Forest Labs. Holdings, Ltd. v. Strides Pharma Global PTE Ltd., 17-7996 (D.N.J.) | Oct. 6, 2017 | Hon. Brian R. Martinotti | Savella® (milnacipran HCl tablets) |
6,602,911
7,888,342
7,994,220
|
| Indivior Inc. v. Par Pharm., Inc., 17-7997 (D.N.J.) | Oct. 6, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,687,454 |
| Insys Therapeutics, Inc. v. Alkem Labs. Ltd., 17-1419 (D. Del.) | Oct. 10, 2017 | Hon. Leonard P. Stark | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Purdue Pharma L.P. v. Amneal Pharms., LLC, LLC 17-1421 (D. Del.) | Oct. 10, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) |
9,763,886
9,763,933
9,675,610
|
| Noven Pharms., Inc. v. Alvogen Pine Brook LLC, 17-1429 (D. Del.) | Oct. 11, 2017 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) |
9,730,900
9,724,310
|
| Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 17-2641 (D. Nev.) | Oct. 11, 2017 | Hon. Miranda M. Du | Vascepa® (icosapent ethyl capsules) |
8,293,728
8,318,715
8,357,677
8,367,652
8,377,920
8,415,335
8,426,399
8,440,650
8,518,929
8,524,698
8,546,372
8,617,594
|
| Hoffmann-La Roche Inc. v. Airis Pharma Private Ltd., 17-7912 (S.D.N.Y.) | Oct. 13, 2017 | Hon. Katherine B. Forrest | Valcyte® (valganciclovir HCl oral solution) |
9,642,911
8,889,109
|
| Boehringer Ingelheim Pharms., Inc. v. MSN Labs. Private Ltd., 17-8399 (D.N.J.) | Oct. 16, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Sawai USA, Inc. v. Astellas Pharma Inc., IPR2018-00079 (PTAB) | Oct. 16, 2017 | N/A | Myrbetriq® (mirabegron extended-release tablets) | 6,346,532 |
| Takeda Pharms. U.S.A., Inc. v. Macleods Pharms. Ltd., 17-1469 (D. Del.) | Oct. 17, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Acrux DDS Pty Ltd. v. Sandoz, Inc., 17-3824 (S.D. Ind.) | Oct. 23, 2017 | Hon. Sarah Evans Barker | Axiron® (testosterone topical solution) |
8,435,944
8,993,520
9,180,194
|
| Bristol-Myers Squibb Co. v. Apotex Inc., 17-1493 (D. Del.) | Oct. 24, 2017 | Hon. Leonard P. Stark | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Sanofi-Aventis U.S. LLC v. Mylan N.V., 17-9105 (D.N.J.) | Oct. 24, 2017 | Hon. Stanley R. Chesler | Lantus® (insulin glargine injection)XXLantus® SoloSTAR® (insulin glargine injection) |
7,476,652
7,713,930
7,918,833
8,512,297
8,556,864
8,603,044
8,679,069
8,992,486
9,011,391
9,233,211
9,408,979
9,526,844
9,533,105
9,561,331
9,604,008
9,604,009
9,610,409
9,623,189
|
| Acrux DDS Pty Ltd. v. Sandoz, Inc., 17-2558 (D. Col.) | Oct. 25, 2017 | Hon. Nina Y. Wang | Axiron® (testosterone topical solution) |
8,435,944
8,993,520
9,180,194
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00119 (PTAB) | Oct. 25, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 7,964,580 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00120 (PTAB) | Oct. 25, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 7,964,580 |
| Sanofi-Aventis U.S. LLC v. Mylan N.V., 17-0181 (N.D.W.V.) | Oct. 26, 2017 | Hon. Irene M. Keeley | Lantus® (insulin glargine injection)XXLantus® SoloSTAR® (insulin glargine injection) |
7,476,652
7,713,930
7,918,833
8,512,297
8,556,864
8,603,044
8,679,069
8,992,486
9,011,391
9,233,211
9,408,979
9,526,844
9,533,105
9,561,331
9,604,008
9,604,009
9,610,409
9,623,189
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00121 (PTAB) | Oct. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,334,270 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00122 (PTAB) | Oct. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,334,270 |
| Pfizer Inc. v. Breckenridge Pharm., Inc., 17-1532 (D. Del.) | Oct. 30, 2017 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib tablets) |
6,956,041
7,091,208
7,265,221
RE41,783
|
| Recro Gainesville LLC v. Actavis Labs. FL, Inc., 17-1535 (D. Del.) | Oct. 30, 2017 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,713,611 |
| Allergan Sales, LLC v. Sandoz, Inc., 17-10129 (D.N.J.) | Oct. 30, 2017 | Hon. William H. Walls | Combigan® (brimonidine tartrate / timolol maleate ophthalmic solution) | 9,770,453 |
| Forest Labs., LLC v. MSN Labs. Private Ltd., 17-10140 (D.N.J.) | Oct. 30, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00125 (PTAB) | Oct. 30, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,633,309 |
| Pfizer Inc. v. Umedica Labs. Pvt., Ltd., 17-1551 (D. Del.) | Oct. 31, 2017 | Hon. Richard G. Andrews | Viagra® (sildenafil citrate tablets) | 6,469,012 |
| iCeutica Pty Ltd v. Apotex, Inc., 17-1553 (D. Del.) | Oct. 31, 2017 | Vacant Judgeship (2017) | Zorvolex® (diclofenac capsules) |
8,679,544
8,999,387
9,017,721
9,173,854
9,180,095
9,180,096
9,186,328
|
| iCeutica Pty Ltd v. Apotex Inc., 17-1554 (D. Del.) | Oct. 31, 2017 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) |
9,526,734
9,649,318
|
| Forest Labs., LLC v. Prinston Pharm Inc., 17-10230 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Torrent Pharms. Ltd., 17-10273 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Westward Pharms. Int'l Ltd., 17-10321 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Zydus Pharms. (USA) Inc., 17-10330 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Hospira, Inc. v. Presenius Kabi USA, LLC, 17-7903 (N.D. Ill.) | Nov. 1, 2017 | Hon. Rebecca R. Pallmeyer | Precedex® (dexmedetomidine HCl injection) | 9,616,049 |
| ViiV Healthcare Co. v. Lupin Ltd., 17-1576 (D. Del.) | Nov. 2, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00126 (PTAB) | Nov. 2, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 9,284,342 |
| Pfizer Inc. v. Sun Pharm. Indus. Ltd., 17-1597 (D. Del.) | Nov. 7, 2017 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | RE41,783 |
| Mayne Pharma Int'l Pty Ltd. v. Actavis Elizabeth LLC, 17-1614 (D. Del.) | Nov. 9, 2017 | Vacant Judgeship (2017) | Doryx® MPC (doxycycline hyclate delayed-release tablets) |
6,958,161
9,295,652
9,446,057
9,511,031
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00123 (PTAB) | Nov. 9, 2017 | N/A | Harvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,735,372 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00151 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,138,229 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00152 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,820,788 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00153 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,923,536 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00162 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,820,788 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00163 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,923,536 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00164 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,138,229 |
| AbbVie Inc. v. Cipla Ltd., 17-1631 (D. Del.) | Nov. 10, 2017 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
7,148,359
7,364,752
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| ViiV Healthcare Co. v. Apotex Inc., 17-1634 (D. Del.) | Nov. 10, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets)XXTivicay® (dolutegravir tablets) | 9,242,986 |
| Boehringer Ingelheim Pharms., Inc. v. Teva Pharms. USA, Inc., 17-11510 (D.N.J.) | Nov. 10, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib tablets) |
RE43,431
8,426,586
|
| Mayne Pharma Int'l Pty Ltd. v. Lupin Ltd., 17-1637 (D. Del.) | Nov. 13, 2017 | Vacant Judgeship (2017) | Doryx® MPC (doxycycline hyclate delayed-release tablets) |
9,295,652
9,446,057
9,511,031
|
| AstraZeneca LP v. Prinston Pharm. Inc., 17-1639 (D. Del.) | Nov. 13, 2017 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
RE 46,276
7,250,419
7,265,124
|
| Par Pharm., Inc. v. Indivior Inc., 17-1280 (E.D. Va.) | Nov. 13, 2017 | Hon. Claude M. Hilton | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,687,454 |
| Delcor Asset Corp. v. Glenmark Pharms. Ltd., 17-1653 (D. Del.) | Nov. 15, 2017 | Hon. Richard G. Andrews | Evoclin® (clindamycin phosphate aerosol, foam) |
7,141,237
7,374,747
|
| Forest Labs., LLC v. Aurobindo Pharma USA, Inc., 17-11679 (D.N.J.) | Nov. 15, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Amneal Pharms. LLC, 17-11680 (D.N.J.) | Nov. 15, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Eli Lilly and Co. v. Actavis LLC, 17-4299 (S.D. Ind.) | Nov. 16, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| ViiV Healthcare Co. v. Cipla Ltd., 17-1670 (D. Del.) | Nov. 17, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Mylan Pharms. Inc., 17-1671 (D. Del.) | Nov. 17, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Mylan Pharms. Inc., 17-0197 (N.D.W.V.) | Nov. 17, 2017 | Hon. Irene M. Keeley | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-1678 (D. Del.) | Nov. 20, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-11873 (D.N.J.) | Nov. 20, 2017 | Hon. Brian R. Martinotti | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| Takeda Pharms. U.S.A., Inc. v. Strides Pharma Global PTE Ltd., 17-1690 (D. Del.) | Nov. 21, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00168 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,549,938 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00169 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,566,289 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00170 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,566,290 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00171 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,572,823 |
| Shire Development LLC v. Teva Pharms. USA, Inc., 17-1696 (D. Del.) | Nov. 22, 2017 | Hon. Richard G. Andrews | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) |
6,913,768
8,846,100
9,173,857
|
| Onyx Therapeutics, Inc. v. Aurobindo Pharma USA, Inc., 17-1699 (D. Del.) | Nov. 22, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
7,737,112
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA Inc., 17-12082 (D.N.J.) | Nov. 27, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,788
8,222,219
|
| Forest Labs., LLC v. Mylan Pharms. Inc., 17-1728 (D. Del.) | Nov. 30, 2017 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 9,708,371 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-1737 (D. Del.) | Dec. 1, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-12374 (D.N.J.) | Dec. 1, 2017 | Hon. Brian R. Martinotti | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Cipla Ltd., 17-1741 (D. Del.) | Dec. 4, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-00173 (PTAB) | Dec. 4, 2017 | N/A | Minivelle® (estradiol extended-release film) | 9,724,310 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-00174 (PTAB) | Dec. 4, 2017 | N/A | Minivelle® (estradiol extended-release film) | 9,730,900 |
| Mylan Pharms. Inc. v. Pozen Inc., IPR2018-00272 (PTAB) | Dec. 4, 2017 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,393,208 |
| Leo Pharma A/S v. Actavis Labs. UT, Inc., 17-1752 (D. Del.) | Dec. 6, 2017 | Hon. Joseph F. Bataillon | Picato® (ingenol mebutate gel) |
9,820,959
9,833,428
9,833,429
|
| Leo Pharma A/S v. Perrigo UK Finco Ltd., 17-1753 (D. Del.) | Dec. 6, 2017 | Hon. Joseph F. Bataillon | Picato® (ingenol mebutate gel) |
9,820,959
9,833,428
9,833,429
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00211 (PTAB) | Dec. 6, 2017 | N/A | Harvoni® (ledipasvir / sofosbuvir tablets) | 9,393,256 |
| Chiesi U.S.A., Inc. v. Teva Pharms. USA, Inc., 17-1772 (D. Del.) | Dec. 7, 2017 | Vacant Judgeship (2017) | Bethkis® (tobramycin injection solution) |
6,987,094
7,696,178
7,939,502
|
| Pfizer Inc. v. Aurobindo Pharma USA Inc., 17-1775 (D. Del.) | Dec. 8, 2017 | Hon. Leonard P. Stark | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 17-1777 (D. Del.) | Dec. 8, 2017 | Hon. Leonard P. Stark | Minivelle® (estradiol extended-release film) |
9,730,900
9,724,310
|
| Valeant Pharms. Int'l, Inc. v. Actavis Labs. FL, Inc., 17-12857 (D.N.J.) | Dec. 8, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide tablets) |
9,724,343
9,492,445
|
| Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 17-6921 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Entereg® (alvimopan capsules) |
6,469,030
8,946,262
|
| ViiV Healthcare Co. v. Sandoz Inc., 17-1784 (D. Del.) | Dec. 11, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Sandoz Inc., 17-12912 (D. Del.) | Dec. 11, 2017 | Hon. Brian R. Martinotti | Tivicay® (dolutegravir tablets) | 9,242,986 |
| KVK-Tech, Inc. v. Shire PLC, IPR2018-00290 (PTAB) | Dec. 11, 2017 | N/A | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | 8,846,100 |
| KVK-Tech, Inc. v. Shire PLC, IPR2018-00293 (PTAB) | Dec. 11, 2017 | N/A | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | 9,173,857 |
| Teva Pharms. Int'l GMBH v. Mylan Labs. Ltd., 17-1790 (D. Del.) | Dec. 12, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Neos Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-1793 (D. Del.) | Dec. 13, 2017 | Hon. Gregory M. Sleet | Cotempla XR-ODT® (methylphenidate extended-release orally disintegrating tablets) |
8,840,924
9,072,680
9,089,496
|
| AstraZeneca Pharms. LP v. Fresenius Kabi USA, LLC, 17-1795 (D. Del.) | Dec. 14, 2017 | Vacant Judgeship (2017) | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| AstraZeneca Pharms. LP v. Fresenius Kabi USA, LLC, 17-13075 (D.N.J.) | Dec. 14, 2017 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Amgen Inc. v. Watson Labs., Inc., 17-1807 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Barr Labs., Inc., 17-1808 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Teva Pharms. USA, Inc., 17-1809 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Mitsubishi Tanabe Pharma Corp. v. Macleods Pharms., Ltd., 17-13130 (D.N.J.) | Dec. 15, 2017 | Hon. Peter G. Sheridan | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Bracco Diagnostics Inc. v. Maia Pharms., Inc., 17-13151 (D.N.J.) | Dec. 15, 2017 | Hon. Peter G. Sheridan | Kinevac® (sincalide for injection) | 6,803,046 |
| Arbor Pharms., LLC v. Taro Pharms. U.S.A., Inc., 17-9846 (S.D.N.Y.) | Dec. 15, 2017 | Hon. Sidney H. Stein | Sklice® (ivermectin lotion) |
8,791,153
8,927,595
|
| Gilead Sciences, Inc. v. Mylan Pharms. Inc., 17-0217 (N.D.W.V.) | Dec. 15, 2017 | Hon. Irene M. Keeley | Evotaz® (atazanavir / cobicistat tablets) | 8,148,374 |
| Onyx Therapeutics, Inc. v. Dr. Reddy's Labs., Inc., 17-1811 (D. Del.) | Dec. 18, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Eli Lilly and Co. v. Unichem Labs. Ltd., 17-13312 (D.N.J.) | Dec. 19, 2017 | Katharine S. Hayden | Cialis® (tadalafil tablets) | 6,943,166 |
| Millennium Pharms., Inc. v. Qilu Pharm. Co., Ltd., 17-1830 (D. Del.) | December 20, 2017 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| CyDex Pharms., Inc. v. Teva Pharms. USA, Inc., 17-1832 (D. Del.) | Dec. 20, 2017 | Hon. Leonard P. Stark | Evomela® (melphalan HCl for Injection) |
8,410,077
9,200,088
9,493,582
|
| Onyx Therapeutics, Inc. v. MSN Pharms., Inc., 17-1833 (D. Del.) | Dec. 20, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
| Shire Development LLC v. Rhodes Pharms. L.P., 17-1840 (D. Del.) | Dec. 21, 2017 | Hon. Richard G. Andrews | Adderall XR® (dextroamphetamine saccharate / amphetamine aspartate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) |
RE41,148
RE42,096
|
| Impax Labs., Inc. v. Zydus Pharms. USA, Inc., 17-13476 (D.N.J.) | Dec. 21, 2017 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa capsules) | 9,089,608 |
| Amgen Inc. v. Torrent Pharms. Ltd., 17-1844 (D. Del.) | Dec. 22, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00390 (PTAB) | Dec. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,889,159 |
| Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc., 17-1862 (D. Del.) | Dec. 27, 2017 | Vacant Judgeship (2017) | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
| Osi Pharms., LLC v. Accord Healthcare Inc., USA, 17-1868 (D. Del.) | Dec. 28, 2017 | Hon. Gregory M. Sleet | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Mallinckrodt IP Unlimited Co. v. Aurobindo Pharma USA, Inc., 17-1877 (D. Del.) | Dec. 29, 2017 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) |
6,992,218
9,399,012
9,610,265
|
| Patheon Softgels Inc. v. Apotex Inc., 17-13819 (D.N.J.) | Dec. 29, 2017 | Hon. Michael A. Shipp | naproxen sodium OTC Capsules |
9,693,978
9,693,979
|
Related Attorneys
Counsel
